Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomised, Phase IV Study, to Assess the Efficacy and Safety of Tildrakizumab in Patients With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION)

Next Previous
Trial Profile

An Open-Label, Randomised, Phase IV Study, to Assess the Efficacy and Safety of Tildrakizumab in Patients With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy (TRANSITION)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tildrakizumab (Primary) ; Dimethyl fumarate
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms TRANSITION
  • Sponsors Almirall S.A.

Most Recent Events

  • 26 May 2022 Status changed from active, no longer recruiting to completed.
  • 01 May 2022 This trial has been completed in Germany according to European Clinical Trials Database
  • 24 Mar 2021 Planned End Date changed from 28 Feb 2021 to 28 Feb 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top